Amylin says Symlin use without mealtime insulin not approvable
Oct 1 (Reuters) - Amylin Pharmaceuticals Inc AMLN.O said U.S. health regulators issued a "not approvable" letter for Symlin use without mealtime insulin in patients with type 2 diabetes who have not achieved desired glucose control.
The Food and Drug Administration has approved SymlinPen 120 and SymlinPen 60 pen-injector devices to administer Symlin injection to improve mealtime glucose control, the San Diego-based biotechnology company said in a statement.
Symlin is currently approved in the United States for patients with type 2 or type 1 diabetes who use mealtime insulin and need improved glucose control. (Reporting by Bhaswati Mukhopadhyay in Bangalore)
- Ukraine says Russian tanks flatten town; EU to threaten more sanctions |
- EU wields Russia sanctions threat but timing vague |
- F-16s dispatched for unresponsive pilot of small plane near D.C.
- Polish president warns Germany of Putin's 'empire' ambitions
- Russian politician beaten after report on soldier burials